Olaparib research update: mechanism, structure and clinical trials

IF 3.1 4区医学 Q3 CHEMISTRY, MEDICINAL

Medicinal Chemistry Research Pub Date : 2025-01-26 DOI:10.1007/s00044-025-03375-8

Hao Che, Li-Wei Wang, Xiang-Yang Ye, Xingrui He

引用次数: 0

Abstract

Current cancer treatments are known for their low selectivity, and life-threatening toxicity. To solve these issue, various innovative approaches were applied. One of them is the inhibition of DNA repair mechanisms, which have been developed as a new hotspot for its selective inhibition and low toxicity. Notably, PARP inhibition has shown potential for effective targeted cancer therapy. Olaparib, the first FDA-approved PARP inhibitor, has been available for nearly a decade, demonstrating superior efficacy in treating breast and ovarian cancers. This article reviews the latest mechanistic studies, structural modifications, and clinical trials of Olaparib.

Abstract Image

查看原文本刊更多论文

奥拉帕尼研究进展：机制、结构和临床试验

目前的癌症治疗方法以其低选择性和危及生命的毒性而闻名。为了解决这些问题，采用了各种创新方法。其中之一是抑制DNA修复机制，因其选择性抑制和低毒性而成为新的研究热点。值得注意的是，PARP抑制已显示出有效靶向癌症治疗的潜力。奥拉帕尼（Olaparib）是首个获fda批准的PARP抑制剂，已有近十年的历史，在治疗乳腺癌和卵巢癌方面表现出卓越的疗效。本文综述了奥拉帕尼的最新机制研究、结构修饰和临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Chemistry Research 医学-医药化学

CiteScore

4.70

自引率

3.80%

发文量

162

审稿时长

5.0 months

期刊介绍： Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.